Limits...
Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.

Shureiqi I, Cantor SB, Lippman SM, Brenner DE, Chernew ME, Fendrick AM - Br. J. Cancer (2002)

Bottom Line: This incremental cost markedly decreased to $138 191, for patients between the ages of 40--59, and to $86 829 for patients older than 60 years.Variations in the cure rate differences between the doxorubicin and alternative regimens had insignificant effects on the improvement in 5-year survival rates from multiple gated acquisition-scan screening.The use of multiple gated acquisition scans for pretreatment screening appears to be more cost-effective for patients who are 40 years or older, when cumulative doxorubicin dose is 350 mg m(-2) or less.

View Article: PubMed Central - PubMed

Affiliation: The University of Texas M. D. Anderson Cancer Center, Department of Clinical Cancer Prevention, 1515 Holcombe Boulevard, Box 236, Houston, TX 77030, USA. ishureiqi@mdanderson.org

Show MeSH

Related in: MedlinePlus

Cost-effectiveness estimates for MUGA scan monitoring in patients given doxorubicin dose of ⩽350 mg m−2 ($/life saved).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375190&req=5

fig3: Cost-effectiveness estimates for MUGA scan monitoring in patients given doxorubicin dose of ⩽350 mg m−2 ($/life saved).

Mentions: Improvement in 5-year survival rates with MUGA screening in patients given doxorubicin for two cumulative dose thresholds (⩽350 and 500 mg m−2).


Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.

Shureiqi I, Cantor SB, Lippman SM, Brenner DE, Chernew ME, Fendrick AM - Br. J. Cancer (2002)

Cost-effectiveness estimates for MUGA scan monitoring in patients given doxorubicin dose of ⩽350 mg m−2 ($/life saved).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375190&req=5

fig3: Cost-effectiveness estimates for MUGA scan monitoring in patients given doxorubicin dose of ⩽350 mg m−2 ($/life saved).
Mentions: Improvement in 5-year survival rates with MUGA screening in patients given doxorubicin for two cumulative dose thresholds (⩽350 and 500 mg m−2).

Bottom Line: This incremental cost markedly decreased to $138 191, for patients between the ages of 40--59, and to $86 829 for patients older than 60 years.Variations in the cure rate differences between the doxorubicin and alternative regimens had insignificant effects on the improvement in 5-year survival rates from multiple gated acquisition-scan screening.The use of multiple gated acquisition scans for pretreatment screening appears to be more cost-effective for patients who are 40 years or older, when cumulative doxorubicin dose is 350 mg m(-2) or less.

View Article: PubMed Central - PubMed

Affiliation: The University of Texas M. D. Anderson Cancer Center, Department of Clinical Cancer Prevention, 1515 Holcombe Boulevard, Box 236, Houston, TX 77030, USA. ishureiqi@mdanderson.org

Show MeSH
Related in: MedlinePlus